Inspire Medical Systems

Inspire Medical Systems, Inc. is a medical technology company that specializes in developing minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its flagship product, the Inspire system, is a proprietary neurostimulation technology approved by the FDA to treat moderate to severe OSA. The Inspire device is implanted surgically and controlled by the patient with a remote. It works by delivering mild stimulation to the hypoglossal nerve, gently moving the tongue forward and keeping the airway open during sleep.

As of December 2023, Inspire Medical Systems had treated over 60,000 patients with its Inspire therapy. The company reported revenue of USD 624.8 million for the full year 2023, representing a 53% increase over the previous year. In the first quarter of 2024, Inspire's revenue grew by 28% year-over-year, reaching USD 164 million, driven by increased market penetration, expansion into new territories, and greater awareness of its therapy among physicians and patients.

In June 2023, the FDA granted Inspire an expanded indication, increasing the upper limit of the Apnea Hypopnea Index (AHI) to 100 events per hour from 65 and raising the body mass index (BMI) warning in the labeling to 40 from 32. This expansion allows Inspire to treat patients with more severe OSA who previously had limited treatment options.

By the end of the first quarter of 2024, Inspire had 1,246 US medical centers providing its therapy and operated in 298 US sales territories. The company plans to continue its rapid expansion, projecting the activation of 52 to 56 new US centers and the addition of 12 to 14 new US sales territories per quarter for the remainder of 2024.